Privia Health Group, Inc. — Form 8-K Summary
Business Context and Reporting Period
Privia Health Group, Inc. filed this Form 8-K on January 6, 2022, reporting management changes effective January 1–5, 2022. The filing concerns the appointment of a new Chief Financial Officer and related transition arrangements. It does not report quarterly or annual operating results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating performance metrics.
- Jeffrey S. Sherman’s annual base salary: $450,000.
- Annual performance bonus target: 100% of annual base salary.
- Sign-on equity grant: stock options valued at $2.9 million and restricted stock units valued at $1.6 million.
- Potential severance for Mr. Sherman upon qualifying termination: six months of base salary plus continued health benefits.
- David Mountcastle is entitled to his 2021 bonus at the current accrual level, as modified by the Compensation Committee, and may receive a prorated 2022 bonus of up to 25% of his annual bonus amount.
Material Changes Versus the Prior Comparable Period
- Jeffrey S. Sherman was appointed Chief Financial Officer and principal accounting officer effective January 5, 2022, with employment beginning January 1, 2022.
- Mr. Sherman replaced David Mountcastle, who will remain employed through March 31, 2022, to facilitate the transition.
- Mr. Mountcastle’s IPO-related stock options and awards will be forfeited upon his last day, while vested and unvested pre-IPO options may be retained under their existing vesting schedule if transition conditions are satisfied.
Outlook, Commentary, Risks, and Unusual Items
The filing contains no financial guidance or operating outlook. The principal unusual items are the executive compensation and transition arrangements.
- Mr. Sherman may receive annual equity grants and compensation adjustments beginning in 2023, subject to Compensation Committee determination.
- Mr. Sherman is subject to a 12-month post-employment non-compete and a 24-month non-solicitation restriction.
- Mr. Mountcastle’s severance will equal nine months of current salary plus COBRA costs, conditioned on execution of a release of claims. His restrictive covenants remain in effect through December 31, 2023.
- The filing does not quantify the total expected cash cost of the transition, severance, bonuses, health benefits, or equity awards beyond the disclosed amounts.
Key Facts for Investors to Verify
- Review Exhibit 10.1 for the complete terms, vesting provisions, and termination conditions in Mr. Sherman’s employment agreement.
- Review Exhibit 10.2 for the precise calculation of Mr. Mountcastle’s bonuses, severance, COBRA reimbursement, and equity treatment.
- Assess the eventual accounting impact of the sign-on equity awards and transition-related compensation.
- Confirm Mr. Sherman’s ongoing role as principal accounting officer until a successor is appointed.
- Monitor subsequent filings for any additional executive changes, compensation revisions, or disclosure of transition costs.